Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
05/17/18
Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY. The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for ... 
05/09/18
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
– Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma planned for later this year – – FDA dialogue ongoing to support development of SER-287 for Ulcerative Colitis; Company plans to initiate clinical trial in mid-2018 – – Company to host Microbiome R&D Day on May 24 in New York City – ... 
05/07/18
Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 9, 2018 at 8:30 a.m. ET to discuss first quarter 2018 financial results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1599207. ... 
EventsMore
Download DocumentationCorporate Presentation

DateTitleRemind
Me
Prior to
Event
05/24/18 8:00 a.m. ET
Seres Therapeutics, Inc. to host a Microbiome R&D Day
days
Enter your e-mail address 
Stock Quote
NASDAQ:MCRB
$8.24
 + 0.26 (3.26%)
05/23/18 10:26 a.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.